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Abstract:	  
Some human breast cancer cell lines are characterized by lack of p53 function in 
cell cycle control and apoptosis, sometimes due to cytoplasmic sequestration of p53 in 
the cytoplasm. The molecular mechanism causing this phenotype is unknown, but two 
mechanisms have been suggested. One involves a defective protein normally promoting 
nuclear import of p53. Another mechanism that might be involved is cytoplasmic 
tethering of p53 by mitochondrial heat shock protein, mortalin. When mortalin is over-
expressed or otherwise mutated as to hyperactivate the binding site, it binds up all the p53 
so that is unable to enter the nucleus of the cell. In this project, treatments of SKBR3 
breast cancer cells with MKT-077, a competitive binder of mortalin, were used to 
confirm the second mechanism of cytoplasmic sequestration of p53. The migration of 
p53 and subsequent apoptosis was confirmed using immunocytochemistry, Romanowsky 
staining, and a TUNEL assay. The majority of the migration of p53 occurred between 8 
hours and 24 hours of treatment with MKT-077, with some evidence of apoptosis 
occurring after 24 hours.	  
Introduction:	  
The tumor suppressor protein p53 is considered to be one of the most pivotal 
components of cancer progression, as well as being an indicator of resistance to 
traditional treatment methods1. A mutated form is present in 60% of human cancers2. Its 
widespread involvement in malignancy is most likely due to its important role in cell 
cycle regulation, DNA repair, and apoptosis or programmed cellular death. When DNA 
damage is detected, the intracellular concentration of p53 increases and the protein is 
localize in the nucleus in non-malignant cells where the protein acts as transcription 
factor for a variety of proteins that can stop the cell cycle until DNA is repaired or so that 
apoptosis can be initiated if the damage is too extensive2, 3. When p53 is somehow 
prevented from performing its job adequately, the cell is prevented from fixing DNA and 
from undergoing apoptosis1, 3.  
 It is not necessary for p53 to be mutated or absent from the cell for it to be unable 
to perform its transcriptional functions. As it interacts with many other proteins, a change 
in their expression level or in their sequence of amino acids could incapacitate wild type 
p53. One key protein is mortalin (the mitochondrial Hsp70), a member of the heat shock 
family of proteins (Hsps) that have been implicated in stress response within the cell can 
bind to p534. As p53 is responsible for halting the cell cycle following its translocation to 
the nucleus in the cell cycle, having it active within the nucleus constantly is not 
advantageous. Therefore, there are times that p53 needs to be sequestered in the 
cytoplasm. In humans, mortalin routinely binds to p53, as the carboxy terminal end of 
p53 has a binding site for the amino terminal region of mortalin1. This relationship has 
been further supported by observations in clams (Mya arenaria) of the return of p53 to 
the nucleus after cytoplasmic sequestration when the intracellular mortalin concentration 
is decreased by blocking the active binding site or by causing DNA damage that results in 
an increase in p53 concentration that vastly surpasses the amount of available mortalin5. 
This relationship could exist in human cancers, as the binding site for p53 in clam 
mortalin is 97% identical to that of humans5. Also, an interaction between mortalin and 
p53 has been shown to occur in the mitochondria in relation to a nucleus-independent 
apoptotic pathway6. If mortalin is modified in such a way that it no longer releases p53 
when it is required in the nucleus, this abrogate p53 control mechanisms and could cause 
uncontrolled proliferation and an inability of the cell to undergo apoptosis1-5. There is 
evidence of this occurrence in human neuroblastoma, colon carcinoma, osteocarcinoma 
and in breast cancer MCF7 cells where an increase in the concentration of the mortalin-
binding portion of p53 caused wild-type p53 to be released from the cytoplasm and stop 
the cell cycle1. Over sixty percent of patient-derived cancerous tissue tested in one study 
showed an overexpression of mortalin, which when transplanted to nude mice resulted in 
tumors4. 
 As such, exposing cancerous cells to a competitive binder for mortalin could be 
an effective therapy. MKT-077, a water-soluble rhodacyanine dye has been shown to 
inhibit growth of cancerous tissue7. This inhibition is a result of MKT-077 interacting 
with the p53-binding domain of mortalin, disrupting mortalin’s interaction with p53. As 
such, MKT-077 could free p53 from mortalin and allow it to initiate apoptosis either 
through its nuclear function or its mitochondrial function. This research aims to 
determine whether p53 is sequestered in the cytoplasm of SKBR3 breast adenocarcinoma 
cells, whether treatment of the cells with MKT-077 over time will initiate nuclear 





Statement	  of	  Hypothesis:	  
If SKBR3 breast adenocarcinoma cells are treated with MKT-077, it will result in 
translocation of cytoplasmically sequestered p53 to the nucleus followed by apoptosis of 
the breast cancer cells. 	  
Methods: 	  
Cell	  Culture:	  Human	  breast	  adenocarcinoma	  (SKBR3)	  cells	  were	  obtained	  from	  American	  Type	  Culture	  Collection	  (ATCC).	  The	  cells	  were	  cultured	  in	  McCoy’s	  5A	  medium	  (ATCC)	  supplemented	  with	  10%	  fetal	  bovine	  serum	  (FBS)	  (Atlanta	  Biologicals)	  and	  1%	  penicillin/streptomycin	  solution	  (Sigma).	  Cells	  were	  kept	  at	  37°C	  and	  5%	  carbon	  dioxide.	  
Treatment	  with	  MKT-­077:	  MKT-­‐077	  (Sigma)	  was	  added	  directly	  to	  cell	  culture	  flasks	  to	  a	  final	  concentration	  of	  7	  μM	  when	  the	  cells	  were	  60-­‐80%	  confluent.	  Flasks	  were	  covered	  in	  aluminum	  foil	  to	  avoid	  potential	  photoinactivation	  of	  MKT-­‐077.	  Cells	  were	  treated	  for	  two,	  four,	  six,	  eight,	  and	  twenty-­‐four	  hours	  and	  subsequently	  prepared	  as	  cytospins	  along	  with	  untreated	  control	  cells.	  	  
Immunohistochemistry	  to	  determine	  the	  distribution	  of	  p53	  protein:	  Detection	  of	  p53	  protein	  employed	  the	  DO-­‐1	  antibody	  (Santa	  Cruz	  Biotechnology)	  in	  phosphate	  buffered	  saline	  (PBS)	  diluted	  to	  1	  µg/mL.	  Slides	  were	  developed	  with	  the	  Vectastain	  ABC	  Peroxidase	  Mouse	  IgG	  kit	  (Vector	  Laboratories).	  Negative	  control	  slides	  received	  identical	  treatment	  minus	  primary	  antibody.	  Preparations	  will	  be	  observed	  on	  a	  Zeiss	  Axioplan	  II	  microscope	  at	  400X-­‐630X	  to	  detect	  distribution	  of	  p53	  into	  the	  cells.	  
Romanowsky	  Stain:	  Romanowsky	  stain	  (Kwik	  Diff	  staining	  system;	  Thermo)	  was	  used	  to	  observe	  the	  morphology	  of	  both	  control	  and	  treated	  cells.	  Preparations	  were	  observed	  on	  a	  Zeiss	  Axioplan	  II	  microscope	  at	  200-­‐630X.	  
TUNEL	  Assay	  for	  Apoptosis:	  Breast	  cancer	  (SKBR3)	  cells	  untreated	  and	  treated	  with	  MKT-­‐077	  were	  assayed	  using	  the	  fluorescent	  terminal	  dUTP	  nick-­‐end	  labeling	  (TUNEL)	  assay	  (DeadEndTM	  Fluorometric	  TUNEL	  System,	  Promega)	  to	  identify	  DNA	  damage	  as	  an	  indicator	  of	  apoptosis.	  Negative	  controls	  received	  deionized	  water	  instead	  of	  the	  rTdT	  enzyme.	  A	  drop	  of	  ProLong?	  Antifade	  Gold	  Reagent	  (Life	  Technologies)	  was	  added	  to	  each	  slide	  and	  covered	  with	  a	  coverslip	  as	  a	  counterstain.	  After	  incubation	  at	  room	  temperature	  in	  the	  dark	  for	  24	  hours,	  the	  coverslips	  were	  sealed	  to	  the	  slides	  with	  clear	  nail	  polish.	  Preparations	  were	  observed	  on	  a	  Zeiss	  Axioplan	  II	  at	  400X-­‐630X	  to	  detect	  fluorescein	  and	  DAPI	  fluorescence.	  
RNA Extraction: RNA was extracted from SKBR3 breast carcinoma cells for analysis 
with qPCR. The media was removed and 1 mL of TRIzol (Ambion, Life Technologies) 
for each 10 cm2 of surface area of the container that held the growing cells was added and 
agitated until the cells lysed. After a five minute incubation period, the cell lysates were 
separated into even volumes.   For every milliliter of TRIzol used, 0.2 mL of chloroform 
was divided evenly amongst the samples. They were vortexed for fifteen seconds, 
incubated on ice for fifteen minutes, and centrifuged at 12,000 RCF for 15 minutes at 
4°C. Each aqueous layer was combined with an amount of 100% isopropanol equal to 0.5 
mL for every 1 mL of TRIzol used that was split evenly among the samples. The samples 
were kept at -20°C for 2 hours. After thawing the samples, the samples were centrifuged 
at 12,000 RCF at 4°C for 15 minutes or until pellets developed. The pellets were washed 
with 1 mL of 75% ethanol for every milliliter of TRIzol used split evenly among the 
samples by vortexing and then centrifuged at 7500 RCF for five minutes at 4°C. The 
ethanol was removed and the pellets were allowed to air dry. After drying, each pellet 
was resuspended 75 µL in RNase-free water. A 1:100 dilution of each sample was 
analyzed using an Ultrospec 3100. The extracted RNA was stored at -80°C. 
DNase Treatment: One microgram of RNA was combined with 1 µL of 10X DNase I 
reaction buffer from a DNase I kit (Invitrogen) and 9 µL of nuclease-free water. One 
microliter of DNase I, Amplification Grade was added and the mixture was incubated for 
a maximum of fifteen minutes. After, a microliter of 25 mM EDTA was added and the 
mixture was incubated at 65°C for ten minutes. The samples were stored at -80°C. 
cDNA Synthesis: cDNA was synthesized using SuperScript First Strand Synthesis 
System for RT-PCR (Invitrogen). Eight microliters of DNase treated RNA was combined 
with 1 µL of 50 µM oligo(dT) and 1 µL of 10 mM dNTP mix and incubated at 65°C for 
five minutes. The mixture was placed on ice until needed. Separately, with n equaling the 
number of reactions plus one, 2n microliters of 10X RT buffer was combined with 4n 
microliters of 25 mM magnesium chloride (MgCl2), 2n microliters of 0.1 DTT, 1n 
microliters RNaseOUT and 1n microliters of SuperScript III RT and then mixed. Ten µL 
of this mixture was added to the mix containing the DNase treated RNA samples, which 
were mixed and centrifuged briefly. The samples were incubated at 50°C for one hour 
and then incubated for 85°C. The samples were then kept on ice for a minute followed by 
a brief centrifugation and a twenty minutes incubation period at 37°C. The cDNA 
samples were stored at -20°C. 
Real-time quantitative polymerase chain reaction: A 1:10 dilution of a combination of 
all DNase treated RNA samples was made. A 1:5 dilution containing equal amounts of all 
cDNA samples, called solution one, was made with RNase-free water (Fischer), vortexed 
and centrifuged. Fifteen microliters of solution one were mixed with 15 µL of RNase-free 
water to create solution two, which was vortexed and centrifuged briefly. Fifteen 
microliters of solution two were vortexed with fifteen µL of RNase-free water and 
centrifuged to make solution three. Fifteen microliters of solution three and 15 µL of 
RNase-free water were vortexed and centrifuged for a short time to make solution four. 
To make solution five, 6 µL of solution two was combined with 24 µL of RNase-free 
water, vortexed, and briefly centrifuged. Two microliters of solution 2 and 18 µL of 
RNase-free water were vortexed and centrifuged to make solution six.  
Primers for p53, mortalin, and GAPDH (Qiagen) were used, with GAPDH acting 
as a reference, resulting in three separate master mixes. In the following cases, n 
represents number of wells in a 96 well plate to be used plus one. To make the master 
mix solution for the mortalin primer so that the concentration in the well was 200 nM, 5n 
microliters of RT2 SYBR Green ROX qPCR Mastermix (Qiagen), 4.4n microliters of 
RNase-free water, and 0.2n microliters of the 10 µM mortalin primer were combined, 
vortexed, and centrifuged briefly. For the p53 mastermix solution, so that the 
concentration in the well was 400 nM, 5n microliters of RT2 SYBR Green ROX qPCR 
Mastermix was combined with 0.4n microliters of 10 µM p53 primer and 4.2n microliters 
of RNase-free water. This mastermix was vortexed and centrifuged for a short amount of 
time. Finally, 5n microliters of RT2 SYBR Green ROX qPCR Mastermix, 0.4n 
microliters of 10 µM of GAPDH primer, and 4.2n microliters of RNase-free water were 
combined, vortexed and centrifuged to create a GAPDH mastermix solution that creates a 
400 nM concentration in the wells.  
To arrange a real-time quantitative polymerase chain reaction (RT-qPCR) for p53, 
9.6 µL of the p53 mastermix solution was combined with 0.4 µL of each cDNA sample 
in duplicate. A no reverse transcriptase control was created in duplicate by combining 9.6 
µL of the p53 mastermix solution with 0.4 µL DNase treated RNA. A PCR negative 
control was created in duplicate by combining 9.6 µL of p53 mastermix solution and 0.4 
µL of double deionized water. To create a triplicate of standard curves, 9.6 µL of p53 
mastermix was combined separately with solutions one through six made previously. 
This same process is replicated using the mortalin mastermix and the GAPDH mastermix 
solution. The well plate was centrifuged at 1000 RCF for three minutes. The well plate 
was analyzed using the ABI 7500 Fast Real-Time PCR System and the associated 
software. The data was then graphed and analyzed for efficiency and consistency. 
Nuclear and Cytoplasmic Protein Extraction: One milliliter of SKBR3 cell suspension 
was centrifuged at 2000 RCF for ten minutes at 4°C, after which the supernatant was 
removed. The pellet was combined with 200 µL of ice-cold CER I from the NE-PER 
Nuclear and Cytoplasmic Extraction Reagents kit (Thermo) and vortexed. The sample 
was kept on ice for ten minutes, combined with 11 µL of CER II, vortexed and kept on 
ice for one minute. Then the sample was centrifuged for five minutes at 18,000 RCF at 
4°C. The supernatant containing the cytoplasmic proteins was separated out and stored at 
-80°C. The pellet was resuspended in 100 µL ice-cold NER and the mixture was 
vortexed. The sample was kept on ice for 40 minutes, with the sample being vortexed 
every ten minutes. After, the sample was centrifuged at 18,000 RCF for ten minutes at 
4°C. The supernatant, which contained the nuclear proteins, was separated and stored at -
80°C.  
RNA Interference: A six-well plate was seeded with 3.7×105 cells per well. The cells 
were kept in 2300 µL of McCoy’s	  5A	  media at 37°C and 5 % carbon dioxide until the 
transfection complex was made. The transfection complex contained 150 ng of HSPA9 
Silencer Select Pre-designed siRNA (Ambion, Life Technologies) dissolved in 100 µL of 
media mixed with 12 µL of HiPerfect Transfection Reagent (Qiagen) per well used so 
that when added to the cells the siRNA will be at a 5 nM concentration. The transfection 
complex was vortexed and incubated at room temperature for five to ten minutes. This 
mixture is then added to every well dropwise and the plate was swirled to evenly 
distribute the complexes. The cells were kept at 37°C and 5% carbon dioxide for 24 
hours, after which they were used for RNA extractions and cytospins.   
	  
Results:	  
	   Cytospins	  analyzed	  using	  the	  Romanowsky	  stain	  aid	  in	  the	  depiction	  of	  cellular	  morphology	  by	  staining	  the	  nucleus	  dark	  blue	  or	  purple	  with	  the	  cytoplasm	  being	  stained	  light	  blue.	  	  SKBR3	  cells	  appeared	  to	  have	  large	  nuclear	  regions	  and	  unique	  cytoplasm	  characteristics.	  For	  comparison,	  Figure	  1	  shows	  an	  image	  of	  a	  breast	  cancer	  cell	  taken	  with	  an	  electron	  microscope	  that	  Dr.	  Charles	  Walker	  provided.	  	  Slight	  membrane	  irregularities	  are	  present	  because	  SKBR3	  breast	  cancer	  cells	  are	  transformed	  versions	  of	  the	  secretory	  mammary	  cells	  responsible	  for	  milk	  production.	  The	  Romanowsky	  stain	  supported	  these	  observations	  (Figure	  2).	  Changes	  in	  cell	  morphology	  became	  more	  apparent	  as	  time	  treated	  with	  MKT-­‐077	  increased.	  Very	  little	  change	  occurred	  between	  untreated	  cells	  and	  the	  cells	  that	  were	  treated	  for	  two	  hours,	  with	  more	  obvious	  changes	  occurring	  after	  eight	  hours	  of	  treatment	  (Figure	  2),	  and	  becoming	  more	  drastic	  by	  twenty-­‐four	  hours	  of	  treatment	  (Figure	  3).	  Changes	  included	  a	  decrease	  in	  overall	  cell	  size	  to	  nuclear	  size	  ratio	  and	  an	  increased	  number	  of	  membrane	  irregularities.	  	  














Figure	  2:	  Images	  of	  Romanovsky	  stained	  SKBR3	  cells.	  Figure	  2A	  shows	  	  SKBR3	  cells	  treated	  with	  MKT-­‐077	  for	  2	  hours	  at	  200X	  and	  Figure	  2B	  shows	  them	  	  at	  400X.	  Romanovsky	  stained	  SKBR3	  cells	  after	  an	  8	  hour	  MKT-­‐077	  treatments	  are	  also	  shown	  at	  200X	  (Figure	  2C)	  and	  400X	  (Figure	  2D).	  	  
	  	  
	  
Figure	  3:	  SKBR3	  cells	  treated	  for	  24	  hours	  with	  MKT-­‐077	  were	  observed	  at	  200X	  (Figure	  3A)	  and	  400X	  (Figure	  3B)	  after	  a	  Romanowsky	  stain.	  These	  same	  cells	  are	  also	  shown	  at	  630X	  (Figure	  3C)	  with	  one	  image	  focusing	  on	  a	  single	  cell	  (Figure	  3D).	  	  Using	  a	  primary	  antibody	  that	  is	  supposed	  to	  be	  specific	  to	  p53,	  immunohistochemistry	  allows	  for	  the	  staining	  of	  a	  specific	  protein,	  indicating	  its	  location	  within	  a	  cell.	  The	  process	  used	  creates	  a	  dark	  brown	  color	  where	  the	  protein	  is	  localized	  with	  a	  yellow	  color	  marking	  the	  rest	  of	  the	  cell.	  All	  negative	  controls	  that	  did	  not	  receive	  primary	  antibody	  did	  not	  stain.	  The	  stain	  indicated	  p53	  was	  localized	  around	  the	  periphery	  of	  the	  cell	  in	  the	  cytoplasm	  near	  to	  the	  
membrane,	  with	  little	  change	  after	  two	  hours	  of	  MKT-­‐077	  treatment	  (Figure	  4).	  After	  eight	  hours	  of	  treatment,	  distinct	  nuclear	  staining	  was	  present	  with	  diffuse	  staining	  throughout	  the	  cytoplasm,	  indicating	  p53	  movement	  within	  the	  cell	  (Figure	  
4).	  	  Membrane	  irregularities	  increased	  in	  number	  and	  severity	  by	  eight	  hours	  of	  treatment	  as	  well,	  corresponding	  to	  the	  membrane	  irregularities	  seen	  in	  the	  Romanowsky	  stain	  in	  Figure	  2.	  By	  the	  time	  twenty-­‐four	  hours	  of	  treatment	  with	  MKT-­‐077	  had	  passed,	  the	  nuclear	  region	  of	  the	  cells	  was	  very	  darkly	  stained,	  though	  some	  staining	  was	  present	  around	  the	  plasma	  membrane	  of	  the	  cells	  as	  before	  








	  Figure	  4:	  Immunohistochemistry	  stain	  of	  SKBR3	  cells	  after	  2	  hours	  of	  MKT-­‐077	  treatment	  at	  200X	  (Figure	  4A)	  and	  400X	  (Figure	  4B),	  after	  8	  hours	  of	  MKT-­‐077	  treatment	  at	  200X	  (Figure	  4C)	  and	  400X	  (Figure	  4D),	  and	  after	  24	  hours	  of	  MKT-­‐077	  treatment	  at	  200X	  (Figure	  4E)	  and	  400X	  (Figure	  4F)	  	  
A	  TUNEL	  assay	  marks	  DNA	  damage	  in	  a	  cell,	  which	  is	  usually	  indicative	  of	  apoptosis.	  DNA	  damage	  is	  marked	  with	  a	  green	  fluorescence.	  A	  counterstain	  containing	  DAPI	  was	  used	  to	  mark	  the	  nucleus	  with	  blue-­‐purple	  fluorescence.	  All	  fluorescence	  had	  to	  be	  taken	  in	  black	  and	  white,	  but	  the	  fluorescence	  light	  used	  will	  be	  indicated.	  The	  untreated	  cells	  showed	  DAPI	  fluorescence	  but	  no	  FITC	  fluorescence	  was	  present,	  indicating	  no	  or	  very	  low	  levels	  of	  DNA	  damage	  (Figure	  
5).	  	  All	  samples	  that	  did	  not	  receive	  the	  rTdT	  enzyme	  acted	  as	  a	  negative	  control	  and	  did	  not	  exhibit	  FITC	  fluorescence	  (data	  not	  shown).	  FITC	  fluorescence	  was	  also	  absent	  from	  the	  SKBR3	  cells	  that	  were	  treated	  with	  MKT-­‐077	  for	  two	  hours.	  Some	  FITC	  fluorescence	  appeared	  in	  the	  cells	  that	  had	  been	  treated	  for	  four	  hours.	  However,	  it	  is	  not	  in	  the	  nucleus	  where	  the	  genomic	  DNA	  is	  present	  but	  completely	  outside	  of	  it	  (Figure	  5).	  The	  cytoplasm	  was	  speckled	  with	  light	  FITC	  fluorescence.	  	  The	  strength	  of	  the	  FITC	  fluorescence	  increased	  in	  intensity	  and	  remained	  excluded	  from	  the	  nucleus	  after	  six	  hours	  of	  exposure	  to	  MKT-­‐077	  (Figure	  5).	  This	  was	  confirmed	  by	  comparing	  the	  FITC	  and	  DAPI	  fluorescence	  from	  the	  same	  group	  of	  cells.	  After	  eight	  and	  twenty-­‐four	  hours	  of	  MKT-­‐077	  treatment,	  FITC	  fluorescence	  increased	  in	  quantity	  and	  intensity,	  though	  it	  remained	  exclusively	  in	  the	  cytoplasm	  
(Figure	  6).	  	  
	  
Figure	  5:	  SKBR3	  cells	  after	  fluorometric	  TUNEL	  assay	  and	  DAPI	  counterstain.	  Untreated	  SKBR3	  cells	  are	  shown	  under	  DAPI	  fluorescence	  (Figure	  5A)	  and	  FITC	  fluorescence,	  both	  at	  200X.	  FITC	  fluorescence	  of	  SKBR3	  cells	  at	  400X	  after	  MKT-­‐077	  treatment	  for	  2	  hours	  (Figure	  5C)	  and	  for	  4	  hours	  (Figure	  5D).	  The	  same	  cells	  treated	  with	  MKT-­‐077	  for	  6	  hours	  are	  shown	  at	  400X	  under	  both	  FITC	  fluorescence	  (Figure	  5E)	  and	  DAPI	  fluorescence	  (Figure	  5F).	  
	  	  
	  
Figure	  6:	  Fluorometric	  TUNEL	  assay	  on	  SKBR3	  cells	  treated	  for	  MKT-­‐077	  for	  8	  hours	  at	  400X	  under	  FITC	  fluorescence	  (Figure	  6A)	  and	  DAPI	  fluorescence	  (Figure	  6B).	  Cells	  treated	  for	  24	  hours	  observed	  under	  FITC	  fluorescence	  (Figure	  6C)	  and	  DAPI	  fluorescence	  (Figure	  6D)	  at	  200X.	  Two	  images	  were	  also	  viewed	  of	  the	  same	  cells	  at	  400X	  (Figure	  6E	  and	  Figure	  6F	  respectively).	  	  
The	  RNA	  extraction	  of	  the	  SKBR3	  cells	  resulted	  in	  a	  RNA	  concentration	  of	  366	  µg/mL.	  The	  results	  of	  the	  real-­‐time	  quantitative	  polymerase	  chain	  reaction	  (RT-­‐qPCR)	  of	  the	  cDNA	  produced	  from	  the	  extracted	  RNA	  are	  still	  pending.	  	  
	  
Discussion:	  
The	  Romanowsky	  stain	  indicated	  cell	  morphology	  changes	  as	  treatment	  time	  increased.	  	  The	  cells	  initially	  had	  large	  nuclei	  and	  cytoplasmic	  area.	  Their	  membranes	  are	  very	  intact	  with	  some	  slight	  membrane	  bubbling	  as	  the	  cell	  is	  undergoing	  the	  secretion	  process	  (Figure	  2).	  After	  eight	  hours	  of	  treatment,	  the	  cells	  have	  begun	  to	  shrink	  in	  size	  and	  the	  nuclei	  are	  less	  distinct,	  though	  this	  may	  be	  an	  irregularity	  in	  staining.	  Light	  blue	  dye	  was	  seen	  dissipating	  out	  from	  the	  cells,	  indicating	  potential	  cell	  degradation.	  After	  twenty-­‐four	  hours,	  the	  nuclei	  are	  distinct	  and	  there	  are	  even	  some	  cells	  seen	  in	  the	  middle	  of	  cytokinesis	  (Figure	  3).	  The	  cytoplasm	  size	  to	  nuclear	  size	  ratio	  appeared	  to	  have	  decreased.	  Membrane	  bubbling	  has	  increased	  in	  size	  and	  in	  frequency.	  This	  progression	  of	  cell	  morphology	  suggests	  apoptotic	  processes	  were	  initiated	  by	  the	  MKT-­‐077	  treatment.	  This	  suggests	  that	  the	  disruption	  of	  mortalin	  binding	  allowed	  the	  cells	  to	  undergo	  apoptosis.	  	  
Immunohistochemistry	  was	  supposed	  to	  indicate	  the	  location	  of	  p53	  in	  the	  cell.	  Before	  treatment	  and	  at	  low	  treatment	  times,	  the	  staining	  exhibited	  darker	  staining	  lining	  the	  interior	  of	  the	  plasma	  membrane,	  supposedly	  indicating	  that	  p53	  is	  trapped	  in	  the	  cytoplasm	  in	  untreated	  SKBR3	  cells	  (Figure	  4).	  As	  treatment	  time	  lengthens,	  some	  of	  the	  staining	  has	  moved	  to	  the	  nucleus,	  but	  some	  staining	  remains	  in	  the	  cytoplasm.	  Also,	  membrane	  irregularities	  increase	  in	  number	  and	  severity,	  indicating	  a	  loss	  of	  membrane	  integrity.	  According	  to	  this	  assay,	  MKT-­‐077	  treatment	  causes	  some	  translocation	  of	  p53	  to	  the	  nucleus,	  which	  could	  initiate	  apoptosis	  as	  
indicated	  by	  the	  “blebbing”	  of	  the	  mitochondrial	  membrane.	  However,	  as	  will	  be	  addressed	  further	  later,	  there	  is	  some	  question	  as	  to	  whether	  this	  staining	  represents	  p53’s	  location.	  	  
The	  fluorometric	  TUNEL	  assay	  measures	  DNA	  damage	  in	  the	  form	  of	  DNA	  breaks	  by	  tagging	  the	  breaks	  with	  a	  fluorescent	  dye	  fluorescin	  that	  emits	  green	  light	  under	  FITC.	  DAPI	  is	  used	  to	  compare	  the	  location	  of	  the	  FITC	  fluorescence	  to	  the	  nucleus.	  Fluorescence	  increases	  as	  the	  length	  of	  treatment	  time	  increases	  and	  no	  marked	  DNA	  damage	  appears	  before	  four	  hours	  of	  treatment	  (Figure	  5).	  The	  TUNEL	  assay	  does	  not	  indicate	  DNA	  damage	  in	  the	  nucleus,	  but	  rather	  in	  the	  cytoplasm.	  As	  the	  only	  DNA	  in	  the	  cytoplasm	  is	  in	  the	  mitochondria,	  these	  results	  suggest	  that	  in	  the	  times	  and	  concentrations	  used	  in	  this	  study,	  exposure	  to	  MKT-­‐077	  causes	  mitochondrial	  DNA	  damage.	  This	  suggests	  that	  the	  morphological	  signs	  of	  apoptosis	  in	  these	  cells	  could	  be	  caused	  by	  apoptosis	  activity	  initiated	  at	  the	  mitochondria.	  	  
After	  additional	  research,	  these	  changes	  may	  not	  be	  due	  to	  p53	  translocation	  however.	  A	  later	  immunohistochemistry	  assay	  using	  an	  antibody	  from	  a	  different	  company	  indicated	  presence	  of	  p53	  in	  the	  nucleus	  as	  well	  as	  the	  cytoplasm	  in	  untreated	  SKBR3	  cells	  and	  no	  change	  in	  p53	  location	  between	  the	  untreated	  cells	  and	  the	  cells	  that	  had	  been	  treated	  for	  twenty-­‐four	  hours	  (data	  not	  shown).	  Also,	  when	  a	  western	  blot	  was	  performed	  of	  protein	  extracts	  from	  untreated	  cells,	  the	  antibody	  used	  did	  not	  stain	  at	  53	  kDa	  as	  expected	  but	  at	  about	  73	  kDa,	  though	  the	  protein	  that	  did	  react	  with	  the	  antibody	  appeared	  to	  be	  mostly	  in	  the	  cytoplasmic	  
fraction	  (data	  not	  shown).	  Also,	  the	  new	  antibody	  did	  not	  interact	  with	  the	  p53	  standard	  protein.	  Considering	  this,	  it	  is	  impossible	  at	  this	  point	  to	  confirm	  that	  p53	  is	  what	  is	  translocated	  into	  the	  nucleus	  after	  exposure	  to	  MKT-­‐077.	  It	  can	  be	  said,	  however,	  that	  something	  was	  translocated	  to	  the	  nucleus	  after	  exposure	  to	  MKT-­‐077	  and	  that	  DNA	  damage	  indicative	  of	  apoptosis	  occurred	  at	  the	  mitochondria.	  	  
To	  elucidate	  this	  mysterious	  occurrence,	  another	  two	  western	  blots	  could	  be	  performed,	  staining	  each	  membrane	  with	  an	  individual	  antibody	  to	  determine	  which	  stains	  p53	  more	  accurately	  using	  cellular	  extracts	  and	  a	  p53	  protein	  standard.	  Also,	  extracted	  RNA	  was	  used	  to	  generate	  cDNA,	  which	  is	  in	  the	  process	  of	  being	  used	  in	  real-­‐time	  quantitative	  polymerase	  chain	  reaction	  (RT-­‐qPCR)	  to	  determine	  the	  expression	  levels	  of	  mortalin,	  p53,	  and	  GAPDH	  for	  comparison.	  From	  there,	  siRNA	  could	  be	  performed	  using	  a	  complimentary	  sequence	  to	  mortalin	  RNA	  to	  silence	  mortalin	  expression.	  Then	  RT-­‐qPCR	  and	  the	  various	  staining	  techniques	  could	  be	  used	  to	  indicate	  changes	  in	  mortalin	  and	  p53	  expression	  and	  whether	  this	  results	  in	  apoptosis	  in	  theses	  cells.	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